

Early treatment intensification with R-ICE and 90Y-ibritumomab tiuxetan (Zevalin)-BEAM stem cell transplantation in patients with high-risk diffuse large B-cell lymphoma patients and positive interim PET after 4 cycles of R-CHOP-14.

Hertzberg M, Gandhi MK, Trotman J, Butcher B, Taper J, Johnston A, Gill D, Ho SJ, Cull G, Fay K, Chong G, Grigg A, Lewis ID, Milliken S, Renwick W, Hahn U, Filshie R, **Kannourakis G**, Watson AM, Warburton P, Wirth A, Seymour JF, Hofman MS, Hicks RJ; Australasian Leukaemia Lymphoma Group (ALLG)..  
Haematologica. 2017 Feb;102(2):356-363. doi: 10.3324/haematol.2016.154039. Epub 2016 Nov 10.

Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer.

Reck M, Rodríguez-Abreu D, Robinson AG, Hui R, Csőszi T, Fülöp A, Gottfried M, Peled N, Tafreshi A, Cuffe S, O'Brien M, Rao S, Hotta K, Leiby MA, Lubiniecki GM, Shentu Y, Rangwala R, Brahmer JR; KEYNOTE-024 Investigators..  
N Engl J Med. 2016 Nov 10;375(19):1823-1833. Epub 2016 Oct 8.

Unique proteome signature of post-chemotherapy ovarian cancer ascites-derived tumor cells.  
Ahmed N, Greening D, Samardzija C, Escalona RM, Chen M, Findlay JK, **Kannourakis G**.  
Sci Rep. 2016 Jul 29;6:30061. doi: 10.1038/srep30061.

Coalition of Oct4A and  $\beta 1$  integrins in facilitating metastasis in ovarian cancer.  
Samardzija C, Luwor RB, Quinn MA, **Kannourakis G**, Findlay JK, Ahmed N.  
BMC Cancer. 2016 Jul 8;16:432. doi: 10.1186/s12885-016-2458-z.

Evaluation of response from axitinib per Response Evaluation Criteria in Solid Tumors versus Choi criteria in previously treated patients with metastatic renal cell carcinoma.  
Karakiewicz PI, Nott L, Joshi A, **Kannourakis G**, Tarazi J, Alam M.  
Onco Targets Ther. 2016 May 12;9:2855-63. doi: 10.2147/OTT.S102578.

Observation versus late reintroduction of letrozole as adjuvant endocrine therapy for hormone receptor-positive breast cancer (ANZ0501 LATER): an open-label randomised, controlled trial.

Zdenkowski N, Forbes JF, Boyle FM, **Kannourakis G**, Gill PG, Bayliss E, Saunders C, Della-Fiorentina S, Kling N, Campbell I, Mann GB, Coates AS, GebSKI V, Davies L, Thornton R, Reaby L, Cuzick J, Green M; Australia and New Zealand Breast Cancer Trials Group..  
Ann Oncol. 2016 May;27(5):806-12. doi: 10.1093/annonc/mdw055.

Resolution of norfloxacin-induced acute liver failure after N-acetylcysteine therapy: further support for the use of NAC in drug-induced ALF?

Elliott TR, Symes T, **Kannourakis G**, Angus P.  
BMJ Case Rep. 2016 Jan 6;2016. pii: bcr2015213189. doi: 10.1136/bcr-2015-213189.

Anastrozole versus tamoxifen for the prevention of locoregional and contralateral breast cancer in postmenopausal women with locally excised ductal carcinoma in situ (IBIS-II DCIS): a double-blind, randomised controlled trial.

Forbes JF, Sestak I, Howell A, Bonanni B, Bundred N, Levy C, von Minckwitz G, Eiermann W, Neven P, Stierer M, Holcombe C, Coleman RE, Jones L, Ellis I, Cuzick J; IBIS-II investigators..  
Lancet. 2016 Feb 27;387(10021):866-73. doi: 10.1016/S0140-6736(15)01129-0.

Suppression subtractive hybridization method for the identification of a new strain of murine hepatitis virus from xenografted SCID mice.

**Islam MM, Toohey B, Purcell DF, Kannourakis G.**

Arch Virol. 2015 Dec;160(12):2945-55. doi: 10.1007/s00705-015-2592-y.

An emerging role for immune regulatory subsets in chronic lymphocytic leukaemia.

Wallace ME, **Alcantara MB, Minoda Y, Kannourakis G, Berzins SP.**

Int Immunopharmacol. 2015 Oct;28(2):897-900. doi: 10.1016/j.intimp.2015.03.047. Review.

Davis ID, Long A, Yip S, Espinoza D, Thompson JF, Kichenadasse G, Harrison M, Lowenthal RM, Pavlakis N, Azad A, **Kannourakis G**, Steer C, Goldstein D, Shapiro J, Harvie R, Jovanovic L, Hudson AL, Nelson CC, Stockler MR, Martin A.

EVERSUN: a phase 2 trial of alternating sunitinib and everolimus as first-line therapy for advanced renal cell carcinoma.

Ann Oncol. 2015 Jun;26(6):1118-23. doi: 10.1093/annonc/mdv078.

Adjuvant ovarian suppression in premenopausal breast cancer.

Francis PA, Regan MM, Fleming GF, Láng I, Ciruelos E, Bellet M, Bonnefoi HR, Climent MA, Da Prada GA, Burstein HJ, Martino S, Davidson NE, Geyer CE Jr, Walley BA, Coleman R, Kerbrat P, Buchholz S, Ingle JN, Winer EP, Rabaglio-Poretti M, Maibach R, Ruepp B, Giobbie-Hurder A, Price KN, Colleoni M, Viale G, Coates AS, Goldhirsch A, Gelber RD; SOFT Investigators.; **International Breast Cancer Study Group.**

N Engl J Med. 2015 Jan 29;372(5):436-46. doi: 10.1056/NEJMoa1412379.

Polyclonal T-cells express CD1a in Langerhans cell histiocytosis (LCH) lesions.

**West JA, Olsen SL, Mitchell JM, Priddle RE, Luke JM, Akefeldt SO, Henter JI, Turville C, Kannourakis G.**

PLoS One. 2014 Oct 24;9(10):e109586. doi: 10.1371/journal.pone.0109586.

Adjuvant exemestane with ovarian suppression in premenopausal breast cancer.

Pagani O, Regan MM, Walley BA, Fleming GF, Colleoni M, Láng I, Gomez HL, Tondini C, Burstein HJ, Perez EA, Ciruelos E, Stearns V, Bonnefoi HR, Martino S, Geyer CE Jr, Pinotti G, Puglisi F, Crivellari D, Ruhstaller T, Winer EP, Rabaglio-Poretti M, Maibach R, Ruepp B, Giobbie-Hurder A, Price KN, Bernhard J, Luo W, Ribí K, Viale G, Coates AS, Gelber RD, Goldhirsch A, Francis PA; TEXT and SOFT Investigators.; International Breast Cancer Study Group..

N Engl J Med. 2014 Jul 10;371(2):107-18. doi: 10.1056/NEJMoa1404037.

Axitinib versus sorafenib in advanced renal cell carcinoma: subanalyses by prior therapy from a randomised phase III trial.

Escudier B, Michaelson MD, Motzer RJ, Hutson TE, Clark JI, Lim HY, Porfiri E, Zalewski P, **Kannourakis G**, Staehler M, Tarazi J, Rosbrook B, Cisar L, Hariharan S, Kim S, Rini BI. Br J Cancer. 2014 Jun 10;110(12):2821-8. doi: 10.1038/bjc.2014.244.

Acute exercise leads to regulation of telomere-associated genes and microRNA expression in immune cells.

Chilton WL, Marques FZ, **West J, Kannourakis G, Berzins SP**, O'Brien BJ, Charchar FJ.

PLoS One. 2014 Apr 21;9(4):e92088. doi: 10.1371/journal.pone.0092088.

Neoadjuvant chemotherapy with sequential anthracycline-docetaxel with gemcitabine for large operable or locally advanced breast cancer: ANZ 0502 (NeoGem).

McCarthy N, Boyle F, Zdenkowski N, Bull J, Leong E, Simpson A, **Kannourakis G**, Francis PA, Chirgwin J, Abdi E, Gebiski V, Veillard AS, Zannino D, Wilcken N, Reaby L, Lindsay DF, Badger HD, Forbes JF; Australia and New Zealand Breast Cancer Trials Group.. *Breast*. 2014 Apr;23(2):142-51. doi: 10.1016/j.breast.2013.12.001.

Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial.

Davies C, Pan H, Godwin J, Gray R, Arriagada R, Raina V, Abraham M, Medeiros Alencar VH, Badran A, Bonfill X, Bradbury J, Clarke M, Collins R, Davis SR, Delmestri A, Forbes JF, Haddad P, Hou MF, Inbar M, Khaled H, Kielanowska J, Kwan WH, Mathew BS, Mittra I, Müller B, Nicolucci A, Peralta O, Pernas F, Petruzelka L, Pienkowski T, Radhika R, Rajan B, Rubach MT, Tort S, Urrútia G, Valentini M, Wang Y, Peto R; Adjuvant Tamoxifen: Longer Against Shorter (ATLAS) Collaborative Group.. *Lancet*. 2013 Mar 9;381(9869):805-16. Erratum in: *Lancet*. 2013 Mar 9;381(9869):804.

Breast-cancer adjuvant therapy with zoledronic acid.

Coleman RE, Marshall H, Cameron D, Dodwell D, Burkinshaw R, Keane M, Gil M, Houston SJ, Grieve RJ, Barrett-Lee PJ, Ritchie D, Pugh J, Gaunt C, Rea U, Peterson J, Davies C, Hiley V, Gregory W, Bell R; AZURE Investigators.. *N Engl J Med*. 2011 Oct 13;365(15):1396-405. doi: 10.1056/NEJMoa1105195.

Results of the APML3 trial incorporating all-trans-retinoic acid and idarubicin in both induction and consolidation as initial therapy for patients with acute promyelocytic leukemia. Iland H, Bradstock K, Seymour J, Hertzberg M, Grigg A, Taylor K, Catalano J, Cannell P, Horvath N, Deveridge S, Browett P, Brighton T, Chong L, Springall F, Ayling J, Catalano A, Supple S, Collins M, Di Iulio J, Reynolds J; Australasian Leukaemia and Lymphoma Group.. *Haematologica*. 2012 Feb;97(2):227-34. doi: 10.3324/haematol.2011.047506.

Adjuvant trastuzumab in HER2-positive breast cancer.

Slamon D, Eiermann W, Robert N, Pienkowski T, Martin M, Press M, Mackey J, Glaspy J, Chan A, Pawlicki M, Pinter T, Valero V, Liu MC, Sauter G, von Minckwitz G, Visco F, Bee V, Buyse M, Bendaehmane B, Tabah-Fisch I, Lindsay MA, Riva A, Crown J; Breast Cancer International Research Group.. *N Engl J Med*. 2011 Oct 6;365(14):1273-83. doi: 10.1056/NEJMoa0910383.

A cryptic deletion in 5q31.2 provides further evidence for a minimally deleted region in myelodysplastic syndromes.

MacKinnon RN, **Kannourakis G**, Wall M, Campbell LJ. *Cancer Genet*. 2011 Apr;204(4):187-94. doi: 10.1016/j.cancergen.2011.02.001.

The Severe Chronic Neutropenia International Registry: 10-Year Follow-up Report.

Dale DC, Bolyard AA, Schwinzer BG, Pracht G, Bonilla MA, Boxer L, Freedman MH, Donadieu J, **Kannourakis G**, Alter BP, Cham BP, Winkelstein J, Kinsey SE, Zeidler C, Welte K.

*Support Cancer Ther*. 2006 Jul 1;3(4):220-31. doi: 10.3816/SCT.2006.n.020.

Neutrophil elastase mutations and risk of leukaemia in severe congenital neutropenia.  
Rosenberg PS, Alter BP, Link DC, Stein S, Rodger E, Bolyard AA, Aprikyan AA, Bonilla MA, Dror Y, **Kannourakis G**, Newburger PE, Boxer LA, Dale DC.  
Br J Haematol. 2008 Jan;140(2):210-3.

Three cases of activation of cutaneous squamous-cell carcinoma during treatment with prolonged administration of rituximab.  
Fogarty GB, Bayne M, Bedford P, Bond R, **Kannourakis G**.  
Clin Oncol (R Coll Radiol). 2006 Mar;18(2):155-6. No abstract available.

The incidence of leukemia and mortality from sepsis in patients with severe congenital neutropenia receiving long-term G-CSF therapy.  
Rosenberg PS, Alter BP, Bolyard AA, Bonilla MA, Boxer LA, Cham B, Fier C, Freedman M, **Kannourakis G**, Kinsey S, Schwinzer B, Zeidler C, Welte K, Dale DC; Severe Chronic Neutropenia International Registry..  
Blood. 2006 Jun 15;107(12):4628-35.

Severe chronic neutropenia: treatment and follow-up of patients in the Severe Chronic Neutropenia International Registry.  
Dale DC, Cottle TE, Fier CJ, Bolyard AA, Bonilla MA, Boxer LA, Cham B, Freedman MH, **Kannourakis G**, Kinsey SE, Davis R, Scarlata D, Schwinzer B, Zeidler C, Welte K.  
Am J Hematol. 2003 Feb;72(2):82-93. Review.

A time to kill: viral manipulation of the cell death program.  
Hay S, **Kannourakis G**.  
J Gen Virol. 2002 Jul;83(Pt 7):1547-64. Review.

Glycogen storage disease.  
**Kannourakis G**.  
Semin Hematol. 2002 Apr;39(2):103-6. Review.

Mutations in the gene encoding neutrophil elastase in congenital and cyclic neutropenia.  
Dale DC, Person RE, Bolyard AA, Aprikyan AG, Bos C, Bonilla MA, Boxer LA, **Kannourakis G**, Zeidler C, Welte K, Benson KF, Horwitz M.  
Blood. 2000 Oct 1;96(7):2317-22.

Select item 10887102  29.  
Myelodysplasia syndrome and acute myeloid leukemia in patients with congenital neutropenia receiving G-CSF therapy.  
Freedman MH, Bonilla MA, Fier C, Bolyard AA, Scarlata D, Boxer LA, Brown S, Cham B, **Kannourakis G**, Kinsey SE, Mori PG, Cottle T, Welte K, Dale DC.  
Blood. 2000 Jul 15;96(2):429-36.

Novel endogenous type D retroviral particles expressed at high levels in a SCID mouse thymic lymphoma.  
Ristevski S, Purcell DF, Marshall J, Campagna D, Nouri S, Fenton SP, McPhee DA, **Kannourakis G**.  
J Virol. 1999 Jun;73(6):4662-9.

Perivascular T cells express the pro-inflammatory chemokine RANTES mRNA in multiple sclerosis lesions.

Hvas J, McLean C, Justesen J, **Kannourakis G**, Steinman L, Oksenberg JR, Bernard CC. *Scand J Immunol.* 1997 Aug;46(2):195-203.

Leukemia inhibitory factor and interleukin-6 are produced by diseased and regenerating skeletal muscle.

Kurek JB, Nouri S, **Kannourakis G**, Murphy M, Austin L. *Muscle Nerve.* 1996 Oct;19(10):1291-301.

EWS/FLI-1 fusion transcript detection and MIC2 immunohistochemical staining in the diagnosis of Ewing's sarcoma.

Lee CS, Southey MC, Waters K, **Kannourakis G**, Georgiou T, Armes JE, Chow CW, Venter DJ. *Pediatr Pathol Lab Med.* 1996 May-Jun;16(3):379-92.

Cytogenetic and DNA analysis of two neuroectodermal tumors without a simple t(11;22).

Slater HR, Tiong T, Konstantakopoulos S, Sham C, Petrovic V, Voullaire L, **Kannourakis G**. *Cancer Genet Cytogenet.* 1995 Aug;83(1):12-7.

Soluble antigen can cause enhanced apoptosis of germinal-centre B cells.

Pulendran B, **Kannourakis G**, Nouri S, Smith KG, Nossal GJ. *Nature.* 1995 May 25;375(6529):331-4.

bcl-2 transgene expression can protect neurons against developmental and induced cell death.

Farlie PG, Dringen R, Rees SM, **Kannourakis G**, Bernard O. *Proc Natl Acad Sci U S A.* 1995 May 9;92(10):4397-401.

Viable bone marrow stromal cells are required for the in vitro survival of B-cell precursor acute lymphoblastic leukemic cells.

Ashley DM, Bol SJ, **Kannourakis G**. *Leuk Res.* 1995 Feb;19(2):113-20.

Flow cytometric analysis of intercellular adhesion between B-cell precursor acute lymphoblastic leukemic cells and bone marrow stromal cells.

Ashley DM, Bol SJ, Tucker DP, Waugh CM, **Kannourakis G**. *Leukemia.* 1995 Jan;9(1):58-67.

Kiz-1, a protein with LIM zinc finger and kinase domains, is expressed mainly in neurons.

Bernard O, Ganiatsas S, **Kannourakis G**, Dringen R. *Cell Growth Differ.* 1994 Nov;5(11):1159-71.

The role of cytokines in the pathogenesis of Langerhans cell histiocytosis.

**Kannourakis G**, Abbas A. *Br J Cancer Suppl.* 1994 Sep;23:S37-40. Review.

The biology of erythropoietin and its role in the anaemia of prematurity.

**Kannourakis G.**

J Paediatr Child Health. 1994 Aug;30(4):293-5. Review. No abstract available.

Human bone marrow stromal cell contact and soluble factors have different effects on the survival and proliferation of paediatric B-lineage acute lymphoblastic leukaemic blasts.

Ashley DM, Bol SJ, **Kannourakis G.**

Leuk Res. 1994 May;18(5):337-46.

Dose-intensive cyclophosphamide with etoposide and vincristine for pediatric solid tumors: a phase I/II pilot study by the Australia and New Zealand Childhood Cancer Study Group.

White L, McCowage G, **Kannourakis G**, Nayanar V, Colnan L, Kellie S, Shaw P, Seshadri R, Lockwood L, Tiedemann K, et al.

J Clin Oncol. 1994 Mar;12(3):522-31.

Measurement of the growth parameters of precursor B-acute lymphoblastic leukaemic cells in co-culture with bone marrow stromal cells; detection of two cd10 positive populations with different proliferative capacities and survival.

Ashley DM, Bol SJ, **Kannourakis G.**

Leuk Res. 1994 Jan;18(1):37-48.

A novel approach to the measurement of different in vitro leukaemic cell growth parameters: the use of PKH GL fluorescent probes.

Ashley DM, Bol SJ, Waugh C, **Kannourakis G.**

Leuk Res. 1993 Oct;17(10):873-82.

Characterization of stroma-adherent colony-forming cells: a clonogenic assay for early hemopoietic cells?

Tucker D, Bol S, **Kannourakis G.**

Exp Hematol. 1993 Mar;21(3):469-74.

SCL gene in human tumors.

Rockman S, Begley CG, **Kannourakis G**, Mann GJ, Dobrovic AN, Kefford RF, McGrath K.

Leukemia. 1992 Jul;6(7):623-5.

Proliferative properties of unfractionated, purified, and single cell human progenitor populations stimulated by recombinant human interleukin-3.

**Kannourakis G**, Johnson GR.

Blood. 1990 Jan 15;75(2):370-7.

Effects of recombinant human granulocyte colony-stimulating factor on hematopoietic progenitor cells in cancer patients.

Dührsen U, Villeval JL, Boyd J, **Kannourakis G**, Morstyn G, Metcalf D.

Blood. 1988 Dec;72(6):2074-81.

Enhancement of in vitro beta-thalassaemic and normal hematopoiesis by a noncytotoxic monoclonal antibody, 9.1C3: evidence for negative regulation of hematopoiesis by monocytes and natural killer cells.

**Kannourakis G**, Johnson GR, Begley CG, Werkmeister JA, Burns GF.

Blood. 1988 Oct;72(4):1124-33.

Pharmacokinetics of human granulocyte-macrophage colony-stimulating factor using a sensitive immunoassay.

Cebon J, Dempsey P, Fox R, **Kannourakis G**, Bonnem E, Burgess AW, Morstyn G. *Blood*. 1988 Oct;72(4):1340-7.

Clinical studies with granulocyte colony stimulating factor (G-CSF) in patients receiving cytotoxic chemotherapy.

Morstyn G, Campbell L, Dührsen U, Souza LM, Alton NK, Villeval JL, Nicola NA, Boyd AW, **Kannourakis G**, Cebon J, et al. *Behring Inst Mitt*. 1988 Aug;(83):234-9.

Activated killer cell lymphoma: an erythrophagocytic syndrome simulating histiocytic medullary histiocytosis.

Boyd AW, Ellis DW, **Kannourakis G**, Begley CG, Mackay IR, Burns GF. *Pathology*. 1988 Jul;20(3):265-70.

Clonal proliferation in vitro of individual murine and human hemopoietic cells after fluorescence-activated cell sorting.

**Kannourakis G**, Johnson GR, Battye F. *Exp Hematol*. 1988 Jun;16(5):367-70.

Evidence for interactions between monocytes and natural killer cells in the regulation of in vitro hemopoiesis.

**Kannourakis G**, Begley CG, Johnson GR, Werkmeister JA, Burns GF. *J Immunol*. 1988 Apr 15;140(8):2489-94.

Fractionation of subsets of BFU-E from normal human bone marrow: responsiveness to erythropoietin, human placental-conditioned medium, or granulocyte-macrophage colony-stimulating factor.

**Kannourakis G**, Johnson GR. *Blood*. 1988 Mar;71(3):758-65.

A human complement-fixing monoclonal anti-human lymphocyte antibody of rat origin. Georgiou G, Robertson D, Pereira A, Scaletti B, **Kannourakis G**, Hosking C, Fowler K. *Immunol Cell Biol*. 1988 Feb;66 ( Pt 1):33-42.

Fractionation of normal and beta-thalassemic human hemopoietic progenitor cells by immunomagnetic beads.

**Kannourakis G**, Bol S. *Exp Hematol*. 1987 Dec;15(11):1103-8.

Transgenic mice expressing a hemopoietic growth factor gene (GM-CSF) develop accumulations of macrophages, blindness, and a fatal syndrome of tissue damage.

Lang RA, Metcalf D, Cuthbertson RA, Lyons I, Stanley E, Kelso A, **Kannourakis G**, Williamson DJ, Klintworth GK, Gonda TJ, et al. *Cell*. 1987 Nov 20;51(4):675-86.

Studies by radioiodination of normal adult, fetal and leukemic cell membranes.

**Kannourakis G**, Cauchi MN.

Exp Hematol. 1978 Sep;6(8):655-60.

Osmotic fragility of leukaemic and normal lymphocytes.

**Kannourakis G**, Cauchi MN.

Pathology. 1978 Apr;10(2):131-4.